Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Type 1 Diabetes
Recruiting1 awardPhase 3
Aurora, Colorado
This trial will assess the effects of semaglutide, a medication not approved by the FDA, on people with type 1 diabetes. It may reduce CV disease and kidney disease and improve glucose control and BMI.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.